## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IfW

re Application of AZARE, et al.

Application No.: 10/849,089

Filed: 05/19/2004

Title: Azaindole-derivatives as factor Xa inhibitors

Examiner: R.

R. T. Shiao

Art Unit:

1626

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

December 6, 2005
Date of Deposit

Cignature

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

 (b)	This Information Disclosure Statement is filed after the period set forth in 37 C.F.R.								
	1.97(b), but is believed to be filed before the mailing date of a final action under §1.113								
	or a	or a notice of allowance under §1.311, whichever occurs first.							
	(1)	The undersigned attorney certifies that each item of information contained in this							
		Information Disclosure Statement was cited in a communication from a foreign							
		patent office in a counterpart foreign application not more than three months prior							
		to the filing of this statement;							
	(2)	The undersigned attorney certifies that no item of information contained in this							
		Information Disclosure Statement was cited in a communication from a foreign							
		patent office in a counterpart foreign application or, to the knowledge of the							
		undersigned attorney after making reasonable inquiry, was known to any							
		individual designated in §1.56(c) more than three months prior to the filing of this							
		statement; or							
	(3)	This Information Disclosure Statement is accompanied by a transmittal letter in							
		which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is							
		authorized.							

Respectfully submitted,

Joseph Rosai, Reg. No. 47,038

Attorney for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3410
Telefax (908) 231-2626

Aventis Docket No. DEAV2003/0033 US NP

Please	tvoe a	nlus	sion	(+)	inside	this box	->	$\Box$
	'JP 0 0	PIGO	Sign	٠,	1113146	11113 000	-	

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

E IAO2 Under the

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	
-------	---	----	--

Complete if Known					
Application Number	10/849,089				
Filing Date	05-19-2004				
First Named Inventor	NAZARÉ				
Group Art Unit	1626				
Examiner Name	R. T. Shiao				
Attorney Docket Number	DEAV2003/0033 - US - NP				

	U.S. PATENT DOCUMENTS								
Examiner Initials	Cite No.1	U.S. Patent Number	Document Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		09/794,214		ZHU, et al.	02-28-2001	-			
		10/326,005		CASTELHANO, et al.	12-20-2002				
		10/510,046		CEZANNE, et al.	10-01-2004				
		6,140,351		ARNAIZ, et al.	10-31-2000	-			
		6,790,853		JACOBSON, et al.	09-14-2004				
		1							

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document  Kind Code Office <sup>3</sup> Number <sup>4</sup> (if known)			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>		
		JP	2004203791A	ostraet\	MAKOTO, et al.	07-22-2004				
		JP	2004210716A(4)	street)	HIDEYUKI, et al.	07-29-2004				
		wo	02/00651		QUAN, et al.	01-03-2002				
		wo	01/19788		ZHU,B.	03-22-2001				
								<u> </u>		
								igspace		
					· · · · · · · · · · · · · · · · · · ·	<b> </b>		<b>├</b> ─		
								₩		
				į į						

Examiner	 Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.